转换为基于贝拉塔塞普的免疫抑制作为肺移植中的氨酸节约疗法:一个多机构的回顾性研究
Moustafa Younis1, Cecelia M Miller1, Christopher I Mederos1
1Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, Fl 32608, United States of America.
Transplant immunology
|December 1, 2025
概括
在肺移植患者中,贝拉塔cept CNI缓解疗法显示功能稳定,拒绝,感染或死亡风险没有增加. 这种方法是可行的,并且耐受性很好,为管理移植后护理提供了可行的替代方案.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 移植免疫学 移植免疫学
- 肺部病理学 肺部病理学
背景情况:
- 氨酸抑制剂 (CNI) 毒性是肺移植 (LTx) 后的一个重大问题,影响患者的治疗结果.
- 贝拉塔塞普特提供了一种节省CNI的替代方案,以减轻LTx接受者的功能障碍风险.
研究的目的:
- 评估贝拉塔塞普特作为肺移植患者中CNI节约性免疫抑制疗法的疗效和安全性.
- 评估贝拉塔塞普对功能的影响,并将关键临床结果与对照组进行比较.
主要方法:
- 一项多机构的回顾性审查分析了接受贝拉塔塞普的LTx患者 (2018年1月-2023年8月).
- 主要结局:估计膜过率 (eGFR) 的变化.
- 二次结局:与对照组相比,急性细胞排斥 (ACR),新生供体特异性抗体 (DSA),抗体介导排斥 (AMR),感染,恶性瘤,慢性肺异位移植功能障碍 (CLAD) 和死亡率.
主要成果:
- 在接受贝拉塔塞普的170名LTx患者中,开始后EGFR中位数稳定 (43,46,43毫升/分钟/1.73m2在基线,6个月,1年;p=0.21).
- 与288个LTx对照组相比,在ACR,DSA,AMR,感染,恶性瘤,CLAD或死亡率方面没有发现显著差异.
结论:
- 贝拉塔塞普特的CNI缓解疗法在LTx接受者中耐受良好并且可行.
- 随着贝拉塔塞普的使用,功能似乎稳定下来,对排斥,感染,恶性瘤,CLAD或死亡率没有增加的安全问题.
更多相关视频
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
14.8K
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
2.2K
相关概念视频
01:28Kidney Transplant I: Introduction
310
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
310
01:26Kidney Transplant II: Surgical Procedure
289
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
289